“Specialty Drugs”

54 result(s)
Female caregiver and elderly patient discussing medical information on a couch
Specialty
Safer Options for Infusion Treatments
Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Briefing
Icon of an infusion bag, overlaying a rising line graph
Specialty
Managing the MS Cost Challenge
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon More
Briefing
Specialty
High-Touch, Whole Patient Care for PAH
PAH is a rare, life-threatening disease, which is incurable. It is difficult to manage and to help ensure the longest survival and best possible quality of life, members need... More
Briefing
Specialty
Multiple Specialty Vendors Mean More Headaches
Multiple Specialty Vendors Mean More Headaches More
Commentary
Specialty
Know the Risks of Specialty Carve-out
Know the Cost and Care Risks of Specialty Carve-out More
Video
Cost Management
Strategy and Balance: Managing Costs for Pulmonary Arterial Hypertension
Managing Treatment Costs for Pulmonary Arterial Hypertension More
Briefing
Cost Management
A Breath of Fresh Air for Patients with Pulmonary Arterial Hypertension
New Dry Powder Inhalation Therapies for PAH in Pipeline More
Briefing
Specialty
The Role of Biosimilars in Lowering Specialty Costs
Biosimilars Can Be Part of a Strategy to Lower Specialty Drug Costs More
Briefing
Innovation
Patient-Reported Outcomes Help Ensure Drug Efficacy
Specialty Pharmacy Harnesses Patient-Reported Data to Drive Better Outcomes and Lower Costs More
Commentary